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Summary
T-cell development from stem cells has provided a highly accessible and detailed view of the
regulatory processes that can go into the choice of a cell fate in a postembryonic, stem cell-based
system. But, it has been a view from the outside. The problems in understanding the regulatory
basis for this lineage choice begin with the fact that too many transcription factors are needed to
provide crucial input: without any one of them, T-cell development fails. Furthermore, almost all
the factors known to provide crucial functions during the climax of T-lineage commitment itself
are also vital for earlier functions that establish the pool of multilineage precursors that would
normally feed into the T-cell specification process. When the regulatory genes that encode them
are mutated, the confounding effects on earlier stages make it difficult to dissect T-cell
specification genetically. Yet both the positive and the negative regulatory events involved in the
choice of a T-cell fate are actually a mosaic of distinct functions. New evidence has emerged
recently that finally provides a way to separate the major components that fit together to drive this
process. Here, we review insights into T-cell specification and commitment that emerge from a
combination of molecular, cellular, and systems biology approaches. The results reveal the
regulatory structure underlying this lineage decision.
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Emergence of T-cell identity: marking the pathway
T cells emerge from a microenvironmentally guided process of specialization from
multipotent hematopoietic progenitors. A range of partially restricted types of immature
hematopoietic precursors can respond to the microenvironment of the thymus by entering
the T-cell pathway and acquiring a T-cell identity (1), and an even broader range of
precursors can reveal this potential if they are experimentally exposed to T-lineage
promoting signals in vitro (2). It is known that an indispensable driver of progression into T-
lineage commitment is signaling resulting from interaction of Notch1 on the hematopoietic
precursors with Delta-family Notch ligands on the surfaces of thymic epithelial cells. An in
vitro system has been developed to support T-cell lineage determination and differentiation
on the basis of coculture of the precursors with stromal cells that have been engineered to
express Delta-like (DL) 1 or DL4 (3-5). However, this Notch input is needed throughout a
sequence of stages in which the cells change in behavior, survival criteria, and gene
expression, and all these changes require explanation. This article reviews current
understanding of the transcriptional regulatory changes that convert a multipotent cell
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without T-cell properties into an irreversibly committed T-cell precursor in which the T-cell
gene expression program is fully under way.
Development of T cells concatenates several distinct phases in which the cells grow or
develop particularly in response to signals that have quite different effects in other phases
(Fig. 1). Initially (Phase 1 pro-T), the cells expand in the intrathymic microenvironment,
proliferating in response to cytokine receptor signals and acquiring T cell characteristics in
response to Notch interaction with Delta-like 4 (DL4) expressed in the intrathymic
environment. Second (Phase 2 pro-T), the cells slow their proliferation and begin efficient
rearrangement of T-cell receptor (TCR) β, γ, and δ genes, while losing sensitivity to
cytokine receptor signals. Third, the cells either arrest and die or else undergo one of two
further differentiation programs, a modestly proliferative one toward the γδ T cell fate or a
highly proliferative one, β-selection, which leads toward the CD4+ CD8+ stage [double
positive (DP)] and an αβ T-cell fate. Whereas all earlier stages depend continually on Notch
signaling, both of these alternative survival pathways depend on the success of the cells at
having assembled a complete TCR signaling complex: either a TCRγδ or a ‘pre-TCR’
signaling complex that includes an intact, functional TCRβ chain. With this TCR-dependent
transition, the Notch signal becomes dispensable, and all further decisions will be dictated
primarily by TCR signaling quality and TCR interaction with ligands in the
microenvironment. For those cells that take the pathway toward the αβ fate, the DP stage
poises the cells for stringent additional steps of positive selection, further lineage sub-
specialization, and a final gauntlet of negative selection.
T-cell identity depends on both negative and positive regulatory functions. In negative
terms, the precursors need to divest themselves of the ability to give rise to non-T
hematopoietic cell types. This is commitment, which is considered in detail below. In
positive terms, the precursors need to acquire the ability to rearrange TCR genes. This
requires the cells not only to turn on RAG1 and RAG2 recombinase genes but also to do so
at a time when the right loci in chromatin are opened, so that the recombinase can be
targeted to rearrange TCR rather than immunoglobulin genes (6,7). Targeting appears to
depend on the creation of cell type-specific docking sites for RAG2, which are formed when
site-specific transcription factor binding recruits histone methyltransferases to create local
H3K4me3 marks (7). To introduce diversity into V(D)J joints in the TCR genes, the cells
also transiently turn on the mutagenic DNA polymerase terminal deoxynucleotidyl
transferase (encoded by Dntt). The precursor cells also need to assemble the signaling
complex components that will make TCR chains competent to deliver signals. This means
turning on expression of proximal TCR signaling kinases, such as Lck, ZAP70, and Itk, T-
cell specific adapters such as LAT, the invariant CD3 components of the TCR complex
itself, i.e. CD3γ, CD3δ, CD3ε, and CD3ζ (CD247), and the surrogate α chain preTCRα
(Ptcra), which will enable successfully generated TCRβ chains to assemble into stable
complexes. With the exception of the RAG genes, Dntt, and Ptcra, this set of genes will
remain active in most if not all T cells permanently and claim a major role as T-cell identity
genes (Table 1).
T-lineage identity also includes other less clearly understood features, which also emerge
during the early process of T-lineage commitment. One prominent feature of T cells, from
mid-development onward, is their acute dependence on TCR signals to determine their
survival, proliferation, or death. Taken in the hematopoietic context, the appearance of this
requirement is curiously abrupt (Fig. 1), since both multipotent hematopoietic precursors
and intrathymic T-cell precursors in precommitment stages can grow vigorously in response
to cytokine (and Notch) signals, without any TCR at all. This early cytokine-supported
phase appears to be particularly favored by the conditions in the most widely used in vitro
culture system for T-cell development, so that populations in these stages are
Rothenberg et al. Page 2
Immunol Rev. Author manuscript; available in PMC 2011 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
disproportionately expanded relative to their steady-state levels in vivo (8-10). More
importantly, this TCR-independent early expansion capability is also likely to provide a
crucial physiological rheostat for T-cell developmental output in vivo. For example, thymic
immigrants in fetal life undergo relatively few rounds of division before generating DP cells,
while adult bone marrow derived precursors expand much more to generate a larger ultimate
burst size of DP cells, but after a longer time. The difference primarily appears to be in the
number of cell cycles traversed during the stages before TCR gene rearrangement (11-13).
Yet shortly after commitment this capacity for continuous expansion is lost, so that
population size as well as developmental status become strictly linked to TCR
rearrangement. For example, RAG-deficient T-cell precursors in vivo proliferate to normal
numbers up to the stage when TCR-dependent selection would occur, but not only fail to
progress further but also fail to accumulate higher numbers at the blocked stage. This is not
only due to limitations on the ‘carrying capacity’ of the thymus, for RAG-deficient
postcommitment pro-T cells are limited in their growth and survival in vitro as well (12, A.
Ross, R. A. Diamond, and E. V. R., unpublished results). New results imply that this
dramatic switch in growth dependence may very well be linked mechanistically to T-lineage
commitment, as described below.
Commitment steps: T-lineage identity by elimination
For a hematopoietic stem cell to choose a T-cell developmental fate, it must give up ∼10
other developmental options. This does not happen all at once but rather by sequential
exclusion events in progressively more restricted progenitors. The ‘negative’ aspects of T-
lineage identity choice are among the best defined in all of hematopoiesis. Decades of
elegant work from multiple laboratories, reviewed in several articles in this volume (14-17)
and elsewhere (18-21), have shown that intrathymic T-cell precursors initially possess
capacities to give rise to natural killer (NK) cells, dendritic cells (DC), macrophages and/or
granulocytes (22-28). Many of these studies have employed single-cell cloning techniques,
in which the same cells that exhibited these non-T potentials were also shown to give rise to
T cells. More rarely, some T-cell developmental intermediates can also give rise to mast
cells (29). Strikingly, however, B-cell potential is much more difficult to demonstrate in any
thymocytes. Many cells that enter the thymus initially appear possess B-cell potential
(30-34), at least in postnatal stages, but this potential appears to be extinguished soon
afterwards; the first fetal immigrants may have undergone loss of B-cell potential
prethymically (35,36). The ability to generate NK, DC, or myeloid cells persists much
longer, but it is a conditional competence, seen only if the cells are transferred to permissive
conditions. Within the thymus itself, most or all of these alternatives for the precursors are
actively suppressed by the effects of signaling from the Notch pathway (30). Notch1
interaction with Delta ligands has the power to limit both NK and myeloid differentiation
severely, blocking myeloid differentiation even under conditions where myeloid
transcription factors are forcibly overexpressed (27,37,38), as well as completely aborting
B-cell development. What reveals separate mechanisms of commitment at work is the
response of pre-commitment T-cell precursors when they are transferred to culture under
permissive conditions, with appropriate cytokines and in the absence of Delta-class Notch
ligands. In these conditions, the continued potentials of the cells for NK and DC
development manifestly emerge, whereas B-cell potential is not restored.
Recent work has yielded newly precise definition of the transition when the last of these
alternative options are lost for mouse T-cell precursors. Fig. 1 summarizes the immature cell
types in the mouse thymus that have measurable T-cell precursor activity at the single-cell
level, i.e. pro-T cells. These are subsets of the ‘double negative’ (DN) (CD4−CD8− surface
TCR-) fraction of thymocytes. Of these, early T-cell precursors (ETPs) (c-Kit-high ‘DN1’ or
‘CD4lo’ cells, CD44+ CD25−) are also highly efficient as precursors of NK and DC cells as
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well as some other myeloid cell types, and many DN2 cells (c-Kit+ CD44+ CD25+) are as
well. DN3 cells (c-Kitlow CD44low CD25+) have lost these options completely and are good
representatives of committed pro-T cells. However, there is also a split in the DN2
population, between cells that retain these alternative potentials and cells that are already T-
lineage committed. This was first demonstrated by the Kawamoto group (39) using an Lck-
GFP transgene to separate the subsets; we have subsequently shown that the same
distinction could be made based on the level of endogenous c-Kit expression (23). DN2 cells
with very high Kit levels (‘DN2a’) remain uncommitted while those that have started to
downregulate Kit (‘DN2b’) are fully committed to a T-cell fate (Fig. 1). The timing is
important, because this means that commitment occurs before the DN3a stage, when the
cells substantially slow proliferation in vivo, upregulate RAG genes and undergo most of
their TCR gene rearrangement (23,39). Progression onward from the DN2b stage does not
require TCR gene rearrangement, but later progression beyond the DN3a stage depends on
this completely. The precise ordering of these subsequent events is not as clear for cells
branching off to take the TCRγδ pathway as for cells taking the αβ pathway, and this
remains an important area for further investigation. Nevertheless, the DN2a progression to
DN2b is the fulcrum of most T-lineage commitment, a one-way passage between what we
may term ‘phase 1’ and ‘phase 2’ pro-T cells (Fig. 1).
Commitment and specification: two mechanisms or one?
The onset of T-cell gene expression is closely intertwined with the commitment process. All
the T-cell identity genes (Table 1) are upregulated during the transition from ETP to DN3a,
with all but ZAP70 achieving their full maximum expression by the DN3a stage. They differ
in terms of whether they are already active in the ETP stage: LAT and Lck are already
expressed in such cells at fairly substantial levels, whereas CD3δ, CD3ε, and Itk are
virtually silent until the DN2 stages begin. Nearly all T-lineage identity genes are detectably
expressed in populations of DN2a cells, but undergo further upregulation to the DN2b and
DN3a stages. These relationships are seen not only in sorted subsets of pro-T cells from
adult thymus but also in fetal thymocytes and in fetal liver-derived hematopoietic precursors
differentiating along the T-cell pathway in vitro. With the recognition that DN2b cells are
committed, and the possibility that some ‘DN2a’ cells might also be shifting to a committed
state, it becomes an interesting question whether individual cells may delay activating genes
like Cd3e and Itk until they become committed, thus linking the two processes even more
tightly. However, within the compact Cd3g-Cd3d-Cd3e gene cluster, the equally T-cell
specific CD3g gene is already activated to a significant extent even in the ETP population.
Thus it seems likely that at least some positive regulation of T-cell-specific genes precedes
lineage commitment.
Commitment by definition is an outcome of negative regulation. It implies that some
differentiation pathway genes that were accessible for use or activation in the multipotent
precursor can no longer be expressed. Furthermore, a cell is not committed until all its fate
options are excluded. In the sequence of events in T-cell development, because the B-cell
fate clearly becomes inaccessible before the NK and DC fates are excluded, there must be a
minimum of two separate exclusion mechanisms that are brought into play. Later, a single
negative regulator could conceivably be imagined to exclude both the NK fate and the DC
fate, although these are so distinct from one another in regulatory terms that it would also be
plausible for different ‘commitment agents’ to be involved.
The genes that such commitment factors repress could be rate-limiting for specific
alternative paths through a variety of mechanisms. Very likely repression targets would be
genes that encode the transcription factors that actively promote the alternative fates. They
might also be genes that encode growth factor receptors that are needed to sustain cells in
Rothenberg et al. Page 4
Immunol Rev. Author manuscript; available in PMC 2011 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
the alternative fate: and there is some evidence to suggest that access to the right growth
factor receptor signals may be even more of a limiting factor for early T-cell precursors to
adopt the DC or myeloid fate than for them to adopt the NK cell fate (23,37,38,40). One
additional way that a common negative regulator could work might be through effects on
another, peculiarly T-cell specific, growth and survival requirement. Because Notch
signaling inhibits many non-T pathways of development even in cells that still possess other
options, the ability to ‘see’ these other options depends on the cells' ability to survive
without Notch signaling. Interestingly, the transition from DN2a to DN2b is accompanied
by a sharply increased dependence on Notch-Delta signals for survival (23). A factor that
forced cells to die when Notch signals are removed could have the net impact of producing a
T-lineage committed phenotype as the price of survival. These possibilities have at last
become open to experimental test, as new light has been shed on the identities of
transcription factors that are likely to play key roles in commitment.
Cell identity regulators: B vs. T-cell models
Two hematopoietic lineages provide models that make lineage commitment easy to
understand. These are B lymphocytes and erythroid precursor cells. Both cell types are
defined by batteries of highly cell-type-specific identity genes that are under direct positive
regulation by a small number of transcription factors, which are themselves expressed
specifically in that lineage. This is particularly notable for B cells, where the two most
prominent regulatory factors are EBF1 and Pax5, factors that have no other known sites of
expression or action among all other hematopoietic cell types (41-43). In erythroid cells,
GATA-1 (aided by cofactors) plays a similar dominant role (44-46). The same factors are
implicated in maintaining lineage fidelity by the repression of genes of alternative lineages
and by repression of stem and progenitor-cell genes (43,47). This means that as few as two
transcription factors can embody and directly link both the positive and the negative
regulatory functions that define cellular identity.
T cells do not fit this model. T cells also depend on known transcription factors, some of
which they use over and over from earliest developmental stages through to mature cell
function (20,48,49). Some of these factors not only act as positive regulators of T-cell genes
but are also expressed in a seemingly T-lineage-specific way. Of these, GATA-3 and TCF-1
(encoded by Tcf7) have been recognized for their lineage-specific importance since the
1990s, and their possible roles in commitment are considered below. However, as we have
discussed elsewhere (50,51), these T-cell ‘specific’ factors are no more essential for T-cell
development than half a dozen others that work across cell lineages and are equally
necessary to generate other specific hematopoietic cell types: these include Myb, Runx1/
CBFβ, Ikaros, Gfi1, E2A and its relatives, and even the ‘myeloid’ factor PU.1 in a transient
role. Even more problematically, gains of function of TCF-1 and GATA-3 do not promote
T-cell development. Instead, forced activation of TCF-1 by stabilized β-catenin causes
dedifferentiation and adoption of cross-lineage characteristics (52-54), while forced
overexpression of GATA-3 causes DN2 T-cell precursors to jump completely out of the
lymphoid ‘track’ and differentiate instead into mast cells (29). This means that the activation
of these transcription factors does not in itself provide an explanation for the choice of a T-
lineage identity.
The classic methods of germline and conditional knockouts of factors known to be important
for T-cell gene expression have thus failed to identify a ‘T-cell master regulator’ that
embodies both cell-type specific positive and negative regulatory functions. However, the
candidate gene list has been limited. Conceivably also, in this cell type there could be a
division of regulatory labor, such that the negative regulatory functions needed for
commitment might be carried out by a factor different from the positive regulatory factors
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that have been implicated in expression of T-cell identity genes. Therefore, to search more
comprehensively for other possible candidates for T-cell-specific regulatory function, in the
past few years we and others have used broad genome-wide screening and de novo cloning
methods (55-59, J. Zhang, A. Mortazavi, B. Williams, I. Antoshechkin, B. J. Wold and E. V.
Rothenberg, manuscript in preparation). Our own screening of these genes has been based
on their patterns of gene expression as correlated with the T-lineage commitment process
(58,59, J. Zhang, A. Mortazavi, B. Williams, I Antoshechkin, B. Wold, and E. V. R.,
manuscript in preparation). This approach has yielded not only new candidates for
potentially interesting regulatory molecules but also a richly detailed new picture of the T-
lineage commitment process.
Complex regulatory dynamics of T-cell specification
T-cell specification and commitment emerge from dynamic changes in transcription factor
expression that can be parsed into at least five major components (Fig. 2).
1. Some of the most dramatic changes are seen in a group of ‘stem/progenitor’-
associated genes that are initially expressed at high levels and then are
downregulated during or immediately after commitment (23,57-59, J Zhang,
manuscript in preparation). Many of these genes are known to be proto-oncogenes
in certain contexts, and many are implicated directly in stem-cell proliferation or
maintenance: the stem cell leukemia (SCL) (encoded by Tal1) and Lyl1 bHLH
transcription factors (60-62); the Ets-family protooncogene Erg (63); Lmo2
(64,65); Meis1 (66,67); Hhex (previously, Hex) (68-70); and the Zn finger
transcription factor Bcl11a (71). The multilineage progenitor and myeloid-cell
factor PU.1 (encoded by Sfpi1), as well as the SNAG-domain Zn finger repressor
Gfi1b used in erythromegakaryocytic and mast cell development, are also in this
group. In detail, the downregulation of these genes is not strictly synchronous, as
PU.1, Gfi1b, and probably SCL undergo downregulation slightly before Lyl1,
whereas Bcl11a and Erg are turned off one stage later (23). This order may be
slightly different in human T-cell development (56).
2. A few transcription factor-coding genes are strongly upregulated (10 fold to >100
fold) during commitment. The most strongly upregulated in the whole genome are
the genes encoding the zinc finger factor Bcl11b and the HMG box factor LEF-1 (J
Zhang et al., manuscript in preparation). The alternative promoter isoform of the E
protein relative HEB (Tcf12), called HEBalt, is also sharply induced. These are first
turned on in the DN2a stage and strongly upregulated by DN2b, although Lef1 also
rises proportionately more than Bcl11b after the DN2b stage (23,58,59). A second
wave of factors is upregulated between DN2b and the DN3a stage, including Ets2,
Ets1, and Pou6f1 (not shown). With the sole exception of HEBalt, the expression of
the factors in this group resembles a step function, with strong expression
continuing through DN3a and the first TCR-dependent selection events and
sustained or higher expression into the DP stage.
3. A much gentler upregulation (3-5-fold) from ETP to DN3a stage distinguishes the
factors traditionally associated with T-cell specification, e.g. GATA3, Runx1, Gfi1,
TCF-1 (Tcf7), and the canonical form of HEB (Tcf12).
4. There is a sustained ‘legacy’ of stem-cell and multipotent progenitor-associated
regulatory gene expression that continues throughout the T-cell specification and
commitment process. Even though many of these legacy genes are turned off later,
during β-selection or γδ-selection, they continue to be expressed at minimally
changing levels from the uncommitted ETP stage through T-lineage commitment
and into the DN3a stage. Myb, E2A itself, and Ikaros are all strongly expressed as
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well but almost unchanging at the RNA level, before, during, and after
commitment. They are therefore present to contribute potential regulatory functions
to the lineage commitment process but are clearly not rate limiting for commitment.
5. There is also a group of regulatory genes (not shown) whose expression peaks
sharply at the DN3a stage, after commitment, and then subsides or disappears if
and only if the cells undergo TCR-dependent selection. SpiB is a prominent
example (58). The transient use of these genes at the DN3a stage is most likely to
be associated with the specific physiological features of that stage, such as TCR
gene rearrangement, γδ vs. αβ lineage separation, cell cycle arrest, and poising of
cells for TCR-dependent selection, rather than with the acquisition of a T-cell
identity as such.
6. After commitment, a separate group of factors (not shown), prominently including
Aiolos (Ikzf3), is upregulated during the DN3a/3b transition if and only if the cells
undergo TCR-dependent selection. Id3, the glucocorticoid receptor (Nr3c1), and
Schnurri-3 (Hivep3), also increase moderately from ETP to DN3 stage but may
play their most important roles only during TCR-dependent selection.
In light of the timing of commitment, the first and second groups of transcription factors
provide the most salient candidates for regulators of T-cell identity, negative and positive
regulators, respectively. Of the first group, SCL and PU.1 have been most closely examined
for effects on T-cell development if their expression is artificially sustained at a high level.
Both of these block T-cell development and promote T-cell leukemia under these conditions
(37,60,72-75). In addition, sustained expression of PU.1 has the power to divert even post-
commitment DN3 cells to develop into myeloid and dendritic cells, in accord with known
PU.1 roles in these alternative pathways (37,38,73,74). In spite of these strong inhibitory
effects, however, even massive overexpression of PU.1 has no lasting inhibitory effects on
T-cell development provided that it is transient (37,73). As PU.1 is also required for
development or expansion of competent T-cell precursors (76,77), and as Lyl1 is also
essential to sustain lymphoid precursor potential in stem cells (62), the early expression of
these factors may be crucial for the self-renewal capacity of precursors during the important
intrathymic phase before commitment. In physiological conditions these factors may provide
a regulated restraint on the timing of progression to a T-lineage committed state (78).
The regulatory genes that undergo upregulation in the second group are the most
provocative source of candidates for drivers of T-lineage commitment. This is a small group,
however, and its members have some surprising features. Most of them are not T-lineage
specific. Ets1, Ets2, and Pou6f1 are all expressed in B cells, NK cells, and/or myeloid cells
as well as in T cells (58,79,80, http://www.immgen.org). Lef1, although not highly
expressed in mature B cells, is highly activated during B-cell development, where its
knockout may have a stronger effect than on T-cell development (81). This leaves Bcl11b as
the one transcription factor gene that appears to be turned on exclusively during T-lineage
commitment, which is also T-lineage specific in its expression and sustained throughout T-
cell maturation and function. Bcl11b is crucial for αβ lineage T-cell development, and a
profound defect has been reported at β-selection when Bcl11b is absent (82,83). Yet
curiously, although TCRβ rearrangement is inhibited in Bcl11b-knockout pro-T cells in vivo,
RAG gene expression is fully induced in the absence of Bcl11b (84). In a developmental
context, there is little evidence for Bcl11b acting as a positive regulator of T-lineage identity
genes in general (84). Thus, the one T-cell specific factor that sits at the cusp of the phase 1/
phase 2 transition may not work by turning on T-lineage-specific genes. Nevertheless, it
provides a crucial function for T-lineage developmental progression as well as commitment.
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Bcl11b functions at the commitment checkpoint
Bcl11b is a zinc finger transcription factor with a DNA binding domain of six zinc fingers
and a partially characterized N-terminal repression domain (85). It is unique among all
important factors that are involved in early T-cell development because of its sharp onset of
mRNA expression in the DN2a stage. In mouse thymocytes, the four exons of the Bcl11b
genetic locus are spliced into four identified mRNAs (86, Li and Rothenberg, unpublished
data). Full length Bcl11b cDNA encodes a protein of 884 amino acid with six C2H2 zinc
fingers, but its level in developing T cells is relatively low; instead, the mRNA containing
exons 1, 2, and 4 (Bcl11b 1-2-4) is the abundant isoform. Bcl11b 1-4 is an isoform which is
specifically implicated in γ-irradiation induced thymic lymphomas (86) and may also be
generated as a result of an intragenic deletion caused by illegitimate RAG recombination
activity (87). Because all six zinc fingers are located in exon 4, Bcl11b 1-2-4 and Bcl11b 1-4
have the same zinc finger domains as the full length four-exon form. Biochemical studies
have shown this factor interacts with Sirt-type HDACs or NuRD to repress gene
transcription through trichostatin-resistant and trichostatin-sensitive mechanisms (85,88).
Many of its known roles are repressive (85,89-91), though not all (92,93). In early T-cell
development, we have found that Bcl11b indeed acts to repress genes associated with stem-
ness and alternative lineage potentials in T-cell precursors, although it remains to be
determined whether it does this directly (84).
If Bcl11b is deleted acutely from otherwise normal precursors just before the initiation of T-
cell development, it has three effects on T-cell specification (84,94,95) (Fig. 3). First, it
blocks progression of the cells in the T-cell pathway (84,95). Second, Bcl11b loss prevents
the cells from losing access to a cluster of myeloid fates (84,95). Third, deletion of Bcl11b
greatly increases access of the cells to an NK fate alternative (94, see reviews by P. Liu and
J. Di Santo in this volume). Induction of the NK-specific transcription factor Zfp105 is a
particularly sensitive indicator for the loss of Bcl11b in pro-T cells (Fig. 4). NK
development also becomes less susceptible to inhibition by Notch signaling when Bcl11b is
absent, and a peculiar class of Kit+ CD11c+/low NK-like cells with exuberant growth
properties can emerge (84,94). These defects closely correspond to failures in the complex
of events that normally occur during the phase 1 to phase 2 transition (Fig. 1).
In vivo, Bcl11b-deficient thymocytes are arrested with a CD25+ CD44low phenotype that
suggests arrest just prior to β-selection (83). These thymus populations include some TCRγδ
cells, consistent with RAG recombinase function and the ability to signal through the TCR
complex (83,89). Although TCRβ rearrangement appears to be reduced, the β-selection
developmental block cannot be fully rescued by a TCRβ transgene (82), suggesting that
Bcl11b deficiency causes a more profound defect as well. As shown by conditional deletion
at a later stage of development, Bcl11b is important for T-cell survival and activation
(90,96). However, at this early stage, the primary effect of Bcl11b is not required for
survival. In vitro, with growth driven by DL1 and a rich cocktail of cytokines, loss of
Bcl11b instead causes T-cell precursors to become blocked in a self-renewing, Kithigh DN2a
state under developmental conditions that should fully support T-lineage progression (84,95)
(Fig. 3, ‘self-renewal’, Fig. 4A, B).
The comparison between in vivo and in vitro phenotypes of Bcl11b-deficient DN cells
suggests some inconsistency in the developmental arrest points (82-84,89,95), but this may
be more apparent than real. One difference is that the IL-7, Flt3, Kit ligand, and Notch
ligand levels in vitro may permit DN2 cells to expand more than in the thymic
microenvironment, where IL-7 signals at least are probably limited (97). Bcl11b-deficient
cell proliferation and differentiation are exquisitely sensitive to the levels of these
environmental signals (84). In addition, the Bcl11b-deficient cells can adopt an ambiguous
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phenotype in which they can downregulate CD44 to levels typical of DN3 cells while Kit
levels remain high, as typical of DN2 cells. Although little is known about how Kit and
CD44 are regulated in DN stages, their levels usually appear to correlate very well to each
other and to the progression of T-cell development. However, even in vivo, Bcl11b-deficient
cells in the thymus can persist for many weeks with a Kit+CD25+CD44low phenotype. Fig. 5
shows populations of donor-type cells from the thymus of a reconstituted radiation chimera,
in which retroviral transduction of Cre had been used to delete Bcl11b and activate a
ROSA26R-YFP reporter in the bone marrow donor cells prior to adoptive transfer. By 10-16
weeks after engraftment, most YFP+ cells from donors with a wildtype Bcl11b genotype and
carriers had become either CD4 or CD8 positive, while some adopted a CD44+ but Kitlow
CD25− phenotype. In contrast, YFP+ Bcl11b-deficient donors consistently gave rise to a
much larger population of DN thymocytes, and these were distinguished by their uniformly
higher expression of Kit. Many were Kit+ CD44+ CD25− cells, which also expressed NK
cell markers (not shown), resembling the NK-like cells that are generated in vitro [‘DN1-
like’ in (84)]. In addition, however, Bcl11b-deleted donor cells could generate a pro-T-cell
population which combined the Kithigh CD25+ phenotype of DN2a cells with the low CD44
level of DN3 cells (Fig. 5C, arrows). Crucially, the expansion of this cohort of cells in vivo
without further developmental progression suggests another difference from normal DN3
cells, a functional equivalent of the DN2a stage at which Bcl11b-deficient cells accumulate
in vitro.
The pivotal DN2 stages: Notch, growth factor response, and Bcl11b
The DN2a stage when Bcl11b is first turned on is the first step unambiguously recognizable
along the T-cell-specific developmental pathway. The characteristic induction of CD25
surface expression at this stage is profoundly dependent on Notch-Delta signaling and on
other rate-limiting conditions that remain less well defined (98,99). These cells already
express nearly maximal levels of the T-cell-specific factors GATA-3 and TCF-1 as well as
nearly maximal levels of the Notch and E protein target gene Hes1 (23). Notch signaling is
needed to initiate Bcl11b expression (59), and P. Li et al. (94) have found physical
interactions of CSL (RBPJκ) at least two cis-regulatory sites in the Bcl11b locus where
Notch complexes may work directly toward turning on this gene. Normally in vivo, transit
through this stage is probably fast, as few cells accumulate as DN2a in steady state before
moving forward through commitment. However, the DN2a state can also be actively
sustained for many rounds of cell division by cytokine-dependent growth in vitro, and so
this population has discrete characteristics of its own that are not just artifacts of a mixture
of progenitor and T-lineage committed cells. Most importantly, normal DN2a cells still
strongly transcribe the full array of progenitor-associated genes (group 1) at levels similar to
those in ETPs. Therefore, the Notch signals that turn on CD25 and activate GATA-3 and
TCF-1 and initiate Bcl11b induction are not in themselves sufficient to dictate the repression
of the progenitor cell genes.
Notch signals in themselves are also not sufficient to impose T-lineage commitment. This
has been proven elegantly by Ikawa et al. (95) using a minimalistic tissue culture system for
cell-free presentation of DL4 to developing precursors. In this system, multipotent
hematopoietic progenitors reach the DN2a stage efficiently and proliferate well to the
cytokines that probably sustain growth in vivo, i.e. Kit ligand, Flt3 ligand, and IL-7.
However, they cannot become committed under these conditions and cannot progress further
in the T-lineage pathway. The progression and commitment defects can be linked to their
failure to activate Bcl11b expression under these conditions (95). In the system used by
Ikawa et al. (95), Bcl11b induction depends on stepping down the intensity of signals from
the IL-7 receptor: at lower IL-7 concentrations the cells can progress. As we have shown
using a different experimental strategy, the progression in response to lower IL-7 depends
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directly on Bcl11b, since Bcl11b-deleted cells remain stuck in DN2a, even when the IL-7
concentration is reduced (84).
If Bcl11b is absent, the complex of specification events that normally accompanies the DN2
stage is split. Several distinct tiers of regulatory events show markedly different effects (Fig.
6). Most of the T-cell transcription factors that are induced or preserved as a legacy from
stem and progenitor cells continue to be expressed normally. This includes the upregulation
of GATA-3, TCF-1, HEB, Gfi1, and Notch targets like Hes-1, the sustained expression of
Myb, Runx1, Ikaros, and E2A, and even the sharper upregulation of HEBalt. The
upregulation of RAG-1, which normally occurs after Bcl11b induction, is also Bcl11b-
independent. Furthermore, a group of T-cell identity genes including Cd3e, Cd3g, and Ptcra
are not affected by Bcl11b deletion in their initial upregulation. But as these genes should
increase expression normally after the DN2a stage, they fail to be upregulated further in
Bcl11b-deficient pro-T cells (84,95). Finally, many of the T-cell genes that normally would
be turned on during the DN2b stage, such as Id3, Zap70, and Ets2, remain at substantially
reduced levels of expression. Thus, Bcl11b may not be an essential driver for the initiation
of specification, but it is required for the completion of specification. Bcl11b is probably
both a downstream target and a mediator of many effects of Notch signaling in early T-cell
development: while progression from ETP to DN2a stage depends on Notch signaling, the
progression from a DN2a regulatory state to a DN2b regulatory state depends on Bcl11b.
Dissection of mechanisms of commitment via Bcl11b
Commitment is correlated with the downregulation of stem/progenitor genes, and in pro-T
cells, this downregulation depends on Bcl11b. It is not the only factor that contributes to T-
lineage commitment, as discussed below. However, the behavioral changes in Bcl11b-
deficient cells are tightly linked to the status of stem/progenitor-associated gene expression.
This is a strong result because, unlike most other good candidates for T-lineage commitment
factors, Bcl11b is not required for survival or proliferation of DN2a stage precursors;
Bcl11b-deficient cells even appear to have a selective advantage in vitro and can be readily
characterized. When Bcl11b deletion causes the cells to be trapped in a self-renewing DN2a
state, even after weeks of growth with Notch-Delta signaling they maintain high expression
of the full set of stem/progenitor regulatory genes (84)(Fig. 6).
PU.1 provides one example of how the stem/progenitor genes can themselves create access
to the regulatory states promoting alternative pathways. The mechanisms through which PU.
1 is silenced in DN2b-DN3a stage T cells appear to depend on Runx1 and possibly TCF-1
(75,100,101). How Bcl11b may promote this repression is not yet clear. Still, PU.1 is not
just a stem/progenitor factor but also a direct driver of the myeloid and dendritic cell gene
expression programs, so that PU.1 repression can be causally connected with loss of these
options. In Bcl11b-deficient DN2 cells, the mechanisms that contribute to PU.1 repression
are not deployed, and these pro-T cells become an abnormally efficient source of Mac-1+
Gr-1+ myeloid cells and dendritic cells (84,95).
Bcl11b complements the effects of Notch signaling in restraining myeloid and dendritic cell
potential. Notch signaling can overcome even forced high-level PU.1 expression to preserve
T-lineage identity (37,38,102), and presumably antagonizes myeloid and dendritic fates even
before Bcl11b is turned on. Although they continuously express high levels of PU.1 and
multiple progenitor-cell associated factors, Bcl11b-deficient DN2a cells still need to be
removed from Notch-Delta signals and supplied with myeloid cytokines, such as M-CSF
(CSF-1), in order to undergo myeloid differentiation (Fig. 6). Therefore, Bcl11b is not
required for the mechanism used by Notch to constrain these fates. It may be that Bcl11b's
role in vivo is primarily to promote one-way exit from the stages in which PU.1 expression
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keeps the myeloid option available. Nevertheless, the power of Notch to protect cells from
myeloid diversion by PU.1 increases sharply at the stages when Bcl11b is induced (37), and
it is possible that Bcl11b participates directly in a mechanism to block myeloid
differentiation (M. M. Del Real, L. Li, and E. V. R., unpublished results).
A different mechanism must be invoked to explain how the NK cell option might be related
to Bcl11b roles in the normal T-cell pathway. Greatly increased access to the NK cell
program is among the most dramatic effects of Bcl11b deletion (94). Unlike the myeloid
options, this diversion is fully supported by the same cytokine environment that would
otherwise support T-cell development, and it can be seen even while Notch signaling is
present, although it is enhanced by reduced access to Notch-Delta interaction (84;94).
Bcl11b-deficient cells upregulate NK-lineage transcription factors Zfp105 (84;94),
Eomesodermin, Zbtb16 (PLZF), and Nfil3 (E4bp4), even before full differentiation to NK-
like phenotype (84)(Fig. 6). However, in contrast to the stem/progenitor genes, these NK-
promoting genes are not part of the normal gene expression program of the ETP and DN2a
stages. Thus, before Bcl11b is normally induced, these genes can be kept silent by other
mechanisms. But are these genes really alien to the T-cell program? Fetal pro-T cells are
biased to generate specialized lineages of γδ T cells, and such γδ T cells do express high
levels of Id2, IL-7Rα, and IL-2/IL-15Rβ, a subset of genes which also support the
intrathymic pathway of NK cell development (103). When Bcl11b deletion in fetally derived
precursors causes Id2, Il7ra, and Il2rb genes to be further activated (84), this could occur by
channeling the cells' regulatory state toward one of the available T-lineage differentiation
programs. However, there remains a question of where the positive signal comes from that
turns the NK-promoting transcription factor genes on. Zbtb16 and Nfil3 are not known to
have any normal roles in ETPs, and Zfp105 and Eomes are normally silent from ETP
through DN3 stages in these precursors (80, http://www.immgen.org, J Zhang, et al.,
manuscript in preparation). Thus, it is likely that Bcl11b loss may indirectly lead to
introduction of additional signals, for example via IL-2/IL-15Rβ signaling, that supply the
positive regulatory inputs that activate de novo expression of Zfp105 and Eomes.
One highly attractive possibility is that Bcl11b indirectly blocks NK differentiation by
promoting the activity of E proteins, which can provide a critical barrier to the NK cell
pathway (104). There is no obvious effect on RNA levels encoding E2A or HEB (Tcf12)
expression themselves when Bcl11b is deleted (84). However, E protein effects on T-cell
development are determined not only by their own expression but also by the levels of
antagonistic or diversionary heterodimerization partners, including both the Id proteins that
antagonize DNA binding altogether and the SCL/Lyl1 subgroup of bHLH factors that
redeploy them to a distinct set of gene targets. When Bcl11b is deleted, there is concerted
upregulation of at least three genes that could collectively act as E protein antagonists or
decoys, including Id2, Tal1 (SCL), and Lyl1. If SCL and Lyl1 collaborate with Id2 to
antagonize E protein activity in this context, this could provide a link between ongoing stem/
progenitor cell gene expression and access to the NK pathway. As E protein activity also
appears to limit myeloid development (105), this mechanism could even preserve the access
of Bcl11b-deficient cells to myeloid fates as well.
Thus, loss of Bcl11b positively endows cells with three different options that would
normally be foreclosed by the DN2b stage: enhanced NK cell differentiation even when
some Notch signaling is present; enhanced myeloid differentiation provided that Notch
signaling is removed; and the option to continue to grow as a poised DN2a cell without
further developmental progression (Fig. 3). Blocked E protein activity could contribute to at
least two of these effects, although other regulatory abnormalities need to be evaluated as
well. It is important to distinguish the options that Bcl11b loss does not provide. Bcl11b-
deficient pro-T cells have not yet shown any ability to transdifferentiate into B cells. It
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follows that the lineage restriction factors that block B-cell development must remain intact
in these cells. Additional hematopoietic fates, nominally more ‘distant’, may also remain
excluded: these must be tested in future work. Without Bcl11b, however, cells cannot cross
the divide from ‘phase 1’ pro-T-cell status to ‘phase 2’ (Figs 1 and 6).
Commitment effectors besides Bcl11b: multiple contributions from broadly
expressed T-lineage transcription factors
Bcl11b does not act alone in T-lineage commitment downstream of Notch, although its role
greatly clarifies the overall biphasic aspect of the process. Recall that positive regulation of
T-cell identity genes begins normally in the absence of Bcl11b (Fig. 6). It follows that most
essential positive regulators of T-lineage genes can be mobilized in a Bcl11b-independent
way. Importantly, additional lines of evidence implicate several of these factors, Runx1,
TCF-1, GATA-3, and E proteins, in specific aspects of commitment as well. All of these
regulatory factors are normally expressed in vivo at substantial levels both before and after
the onset of Bcl11b expression. None appear to be altered in expression by loss of Bcl11b
(84), and only E protein activities, as already noted, would be predicted to be affected by
Bcl11b deletion. Therefore, the roles of the others should provide inputs to the
developmental status of pro-T cells that are distinct and independent from Bcl11b.
Runx/CBFβ compound factor activities are required for at least two aspects of early T-cell
specification and commitment. First, a CBFβ dose-reduction strategy has been useful to
observe specific early T-lineage effects mediated through any of the three Runx family
genes while bypassing the severe hematopoietic effects of full Runx1 deletion. This system
has shown that Runx/CBFβ activity is acutely required for generation of true DN2 stage pro-
T cells (106). Interestingly, some cells can upregulate CD25 in response to Notch/Delta
signals even when CBFβ dosage is extremely low, but these ‘DN2-like’ cells fail to turn on
Bcl11b or CD3ε expression, and are distinct even from normal early DN2a cells because of
their lack of GATA-3 expression (106). Thus, Runx/CBFβ is probably required to work
upstream of both Bcl11b and GATA-3, at the very earliest point in T-cell specification. A
second clear role for Runx/CBFβ complexes is during commitment, to execute
downregulation of PU.1. Runx factors bind to three sites in the major upstream regulatory
region for PU.1 and thus act directly (100,107). The repressive activity in pro-T cells has
been demonstrated in vivo (100) as well as in a cell culture system where high-dose Runx1
has been found to mediate pro-T-cell specific repression of PU.1 through an additional,
functionally dedicated repression cis-regulatory element (101). It is still unclear how this
repressive action of Runx factors at the Sfpi1 locus is timed, since expression of Runx1 and
other Runx factors is already high during phase 1 pro-T-cell development as well as after
commitment. One possibility is that the shifting balance between Runx1 and the other two
Runx factors, Runx2 and Runx 3, is important (58). Alternatively Runx factors could enter
complexes with additional, T lineage-specific factors to trigger nucleation of repression
complexes at the DN2b stage.
TCF family factors are tempting to consider as T-lineage commitment factors. These factors
are bifunctional, with activating roles in the presence of nuclear β-catenin and repressive
roles where β-catenin is not recruited. While still somewhat controversial, the best
established role for TCF-1 and Lef1 is during β-selection, long after commitment (108-111),
and this is also the stage when most effects of experimental manipulation of TCF/β-catenin
interaction are seen (112-115). However, perturbations of this axis can also cause a severe
disruption of T-cell development from an early stage (116,117). Disruption of the TCF-1
coding gene (Tcf7) has a much more severe and consistent effect than perturbation of the β-
or γ-catenin partners. This suggests that a major role of TCF-1 in the earlier stages may
normally be to act as a repressor. Currently, one target that this factor is suggested to repress
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is PU.1 itself, through a site associated with the major upstream regulatory region (75);
however, the effect appears to be a relatively subtle, modulating one. However, as for Runx
factors, TCF-1 expression is extremely high before as well as after T-lineage commitment,
suggesting that it is not rate limiting for this change. Meanwhile, the close TCF-1 relative
Lef1 does increase expression dramatically during T-lineage commitment, but it has even
higher expression in pro-B cells, so this feature is not T-cell specific. An unresolved
question is whether the dramatic upregulation of Lef1, beginning only slightly later than
Bcl11b, might alter the net function of TCF/Lef family members in T-cell precursors so as
to cause repressive effects to become dominant in the DN2b stage. However, the limited
available evidence suggests that TCF-1 and Lef1 work redundantly (118) and primarily
support growth-promoting functions in early T cells (119) as well as in pro-B cells (81).
GATA-3 has been implicated in T-cell specific gene expression (120-122) and has been
known to be essential for T-cell development for over 15 years (49,123-126). However, its
full role has proved difficult to resolve because of its intense dose-dependent effects.
Although cells with reduced GATA-3 expression can acquire a DN2-like phenotype, there
are severe viability effects at both ETP stages and afterwards (127). Conversely,
overexpression of GATA-3 can be as antagonistic to T-cell development as it is to most
developmental alternatives (128,129). GATA-3 is probably involved in two aspects of T-
lineage commitment, working through different mechanisms. Forced GATA-3 expression is
intensely inhibitory for B-cell development (29,129, D. D. Scripture-Adams, A. Arias, K. J.
Elihu, A. Champhekar, M. Zarnegar, & E. V. R., manuscript submitted), consistent with the
hypothesis that the early upregulation of GATA-3 in the ETP stage may be directly linked to
the loss of B-cell potential. Unpublished data cited elsewhere in this volume (16) strongly
support this role. At a later stage, GATA-3 may also play a direct role in excluding myeloid
and dendritic cell fates (130), by repressing PU.1 transcription (29), or by antagonizing any
residual PU.1 protein activity as the GATA-3:PU.1 ratio shifts in the DN2a-DN2b transition.
GATA-3 has also been implicated in restricting access to the plasmacytoid dendritic cell fate
in human cells by antagonizing the PU.1 relative, SpiB (130). Bcl11b deletion leaves
GATA-3 expression unchanged or slightly enhanced, however, and so GATA-3 is
particularly likely to contribute to B-lineage exclusion and any other aspects of commitment
that do not depend on Bcl11b.
While other factors may be suggested to exclude B and myeloid fates, the only pro-T cell
factors besides Bcl11b that are known thus far to antagonize the NK cell developmental
alternative are the E proteins, in T-lineage cells E2A and HEB (Tcf12) primarily (104). The
molecular pathway through which these factors limit NK development is not yet clear. It is
possible that the NK antagonism consists simply of promoting T-lineage progression at the
expense of the NK fate. Similarly, in prethymic precursors loss of E protein favors myeloid
development, suggesting a role for E proteins in antagonizing this option as well (105,131).
But E proteins are also particularly interesting because of their strong contribution to T-cell
gene expression, specifically to expression of the set of genes that characterize the
immediate postcommitment DN3 state. Many T-cell identity genes appear to be regulated
directly by E2A, especially in combination with Notch signaling (132,133). Furthermore, E
protein activity appears to be required to maintain the one-way nature of the DN2 to DN3
progression. When both E2A and HEB are conditionally deleted at the DN3 stage, the cells
reportedly regain the ability to proliferate strongly in response to IL-7, and they revert to an
apparent DN2-like phenotype (134). Whether or not these cells fully regain expanded
developmental potential has not yet been determined. Nevertheless, this report implicates net
E protein activity in another of the same roles as Bcl11b, including enforcement of the
directionality of progression from phase 1 to phase 2 pro-T-cell development.
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Unleashing the expression of T-cell identity by negative regulation?
The central unresolved question of T-cell specification continues to be the identity of the
particular combination of positive regulators that accounts for the surge in expression of T-
cell identity genes between the DN2 and DN3 stages. The positive regulators that are known
to participate, as briefly reviewed in the previous section, are already strongly expressed by
the ETP stage and only modestly altered in their expression afterwards. Massive
discontinuities in gene expression, such as those for the CD3 cluster and Bcl11b, seem
unsatisfying to explain as linear responses to the ∼3 fold increase in GATA-3 or TCF-1 or
the 3-5-fold increase in HEB (Tcf12). One may consider three general solutions. First, there
could be an unknown rate-limiting positive factor involved, although the genome-wide
analysis is rapidly narrowing the possibilities for this. Second, activation of T-cell gene
expression could be multiplicative, dependent on coincident inputs from all of the modestly
upregulated T-cell factors. There are indeed cis-regulatory elements that can carry out this
kind of combinatorial ‘and’ logic with independent inputs (135,136), and the prediction
would simply be that all the positive factors would need to converge on cis-elements of this
type. However, a third possibility is also worth considering, as the data do show some
manifestly dramatic changes in transcription factor expression during T-lineage commitment
that go far beyond 2-5 fold effects. These changes are (i) the downregulation of multiple
stem/progenitor-associated regulatory genes and (ii) the upregulation of one factor, Bcl11b,
that is most likely to act as a repressor. Thus, the third possibility is that these negative
regulatory events could themselves result in the positive regulation of T-cell identity genes.
Formally, this possibility is like the paradigmatic ‘double negative gate’ that operates a
crucial cell fate decision in the sea urchin embryo (137,138). In the classic double negative
gate mechanism, the positive inputs for the regulated genes must all be present in advance,
but all the targets are initially kept silent by a common repressor. Then if a second-tier
repressor is introduced to silence the first, the target gene battery can be explosively
activated, exclusively where the second-tier repressor is present. Signatures of this
mechanism are the Boolean, non-gradual form of the split between the states of target genes
fully repressed in one stage (or territory of the embryo), and fully unleashed in another.
There are notable aspects of early T-cell specification that appear to fit this model: for
example, the fact that most or all known positive regulatory inputs are active in the cells by
the ETP stage, before the cells undergo specification, and the fact that upregulation of the
most specific T-cell identity genes is accompanied predominantly by silencing of stem/
progenitor-cell regulatory genes. But, could Bcl11b be the secondary repressor that relieves
repression for all these targets?
The answer depends on how the stem/progenitor regulatory genes are working in early T-
cell development. There are two aspects of the question. The first is whether mechanisms
can be invoked that would enable these factors to be the ‘first-tier repressors’, i.e. to
interfere with T-cell gene activation. The second is whether such a role makes sense in view
of the sustained expression of these stem-cell genes, through many cell divisions and days of
Notch-Delta signaling, up through the DN2a stage.
Multiple mechanisms do in fact exist that would cause factors in the stem/progenitor group
to block activity of the known T-cell positive regulators on their targets. Already noted in
this review is the ability of SCL (Tal1) and Lyl1 to inhibit the activation of T-cell-specific
target genes by E proteins (60,139). A second mechanism is the ability of high-level PU.1 to
block activity of GATA-3 or vice versa, through protein/protein interaction, depending on
which one is in excess. This mechanism is an extension of the widely discussed ‘switch’ that
emerges from mutual antagonism of PU.1 and GATA-1 (140,141). The PU.1/GATA-3
version has recently been shown to operate in rare peripheral T-cell subsets in which PU.1
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expression is reawakened (142,143). A fourth gene to be sharply downregulated at the
DN2a/2b boundary, Gfi1b, also has several potential antagonistic roles, one as a repressor of
GATA-3 (144) and one as a repressor of its own relative, Gfi1, which is also required for T-
cell specification. Thus, as long as the stem/progenitor group factors are expressed, they
collectively limit the activity of E proteins, GATA-3, and Gfi1 all together, not only by
restraining transcription but also by blocking the activity of whatever positive regulatory
protein is present. This effect could indirectly stall the activation of a broad range of ‘DN3’
genes, and in fact these are the results seen when PU.1 levels are artificially locked at a high
level in pro-T cells (78). All these antagonisms could then be relieved at a stroke by
whatever Bcl11b-dependent mechanism is used to silence this set of stem/progenitor genes.
This proposal thus raises the question of why the T-cell specification program could tolerate
expression of the stem-progenitor genes so long if the goal of the program is truly to
promote T-cell differentiation. The answer here may be to recollect the split between phase
1 and phase 2 (Fig. 1), both of which are integral to pro-T cell development. Precursor
expansion is a profound, system-level requirement in any developmental scheme that
incorporates selection as stringent as the TCR-based β-selection, positive selection, and
negative selection that T-cell precursors will later undergo. Phase 1, the cytokine-supported
expansion of precursors before TCR gene rearrangement, is crucial for the establishment of
a normal T-cell precursor pool. Not only does it make sense to have this phase capitalize on
the use of stem/progenitor self-renewal functions; it also makes sense to force a regulated
delay before the differentiation of the cells to phase 2, when their individual reckonings with
fate may no longer be postponed.
Conclusions
In this review, we propose that T-cell specification occurs in two distinct phases, defined by
the overlap between several distinct ‘layers’ of regulatory factors. One important layer is the
stem/progenitor cell set that promotes cytokine-dependent self-renewal functions, but may
antagonize full differentiation. These factors become overlaid by a second group that
includes the early-acting T-cell factors such as GATA-3 and TCF-1 and inputs from the
Notch pathway. At some point, the convergence of these regulatory inputs and the
attenuation of IL-7 receptor signaling signal the activation of a crucial transitional factor,
Bcl11b, which quickly sets in train a mechanism to silence the stem/progenitor self-renewal
genes. One result is the extinction of the last alternative lineage potentials. Simultaneously,
this clears the way for unleashing full activity of the T-cell factors and their stably expressed
collaborators, such as E proteins, both by transcriptional and protein-level mechanisms. This
newly dominant constellation of factors then works through phase 2 of pro-T-cell
development to establish the definitive T-cell state. This state makes the cells subject to
mandatory TCR-dependent selection and may have a countdown aspect; it no longer permits
open-ended expansion by the previous, TCR-independent mechanism.
There are many links in this chain that require experimental test and validation, as well as
biochemical mechanisms that must be resolved in order to explain the action of the factors in
the functions proposed. The direct targets of Bcl11b need to be identified and the structures
of both activation and repression complexes for T-cell specification need to be established.
The regulatory inputs into Bcl11b itself, as well as the T-cell specific cis-regulatory
elements for Bcl11b, Lef1, and the Cd3 genes, all need to be identified. However, this
framework for considering early T-cell development may provide some order in the
complexity that enables a rational regulatory structure to be discerned.
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Fig. 1. Stages in T-cell specification and commitment
Double negative (CD4−CD8− surface TCR−) stages between thymic entry and the first
TCR-dependent selection events are highlighted. Signals from Notch-Delta interaction are
required throughout both ‘phase 1’ and ‘phase 2’. Proliferation is strongest in phase 1 and in
cells that successfully rearrange TCRβ genes, after β-selection. γδ cells have a somewhat
different program that is not discussed in this review. Mac, macrophage; gran, granulocyte;
Meg, megakaryocyte; eryth, erythrocyte. The DN1 cells that have actual T-cell precursor
activity are KitHigh, i.e. ETPs.
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Fig. 2. Regulatory gene expression changes during T-cell specification
Curves show approximate timing of increases and decreases in expression of the indicated
regulatory genes and key T-cell identity genes, selected from the groups discussed in the
text. Data are from ref. (58) and J. Zhang et al., manuscript in preparation. RNA transcripts
encoding Myb, Ikaros, and E2A (bottom) are expressed at high but relatively stable levels
throughout the indicated stages.
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Fig. 3. Effects of Bcl11b deletion on pro-T cells: increased self renewal, prolonged access to
myeloid and dendritic fates, and enhanced, long-term access to NK cell fates
Bcl11b is not required for Notch signals to inhibit myeloid differentiation, but Bcl11b
deletion weakens the ability of Notch signals to inhibit NK differentiation. Gene regulatory
alterations proposed to underlie these shifts are shown in Fig. 6.
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Fig. 4. Enhanced upregulation of NK-cell specific transcription factor Zfp105 in pro-T cell
populations with reduced Bcl11b gene dosage
This experiment shows efficient upregulation of this normally silent gene even when
experimental deletion of Bcl11b is incomplete. (A) Primary cell populations derived from
fetal liver, differentiating in T-cell conditions with OP9-DL1 stroma) for a week after
treatment with retroviral Cre. Left and right panels show control and Bcl11b-deleted
precursors, respectively (from ref. 84). Positions of populations sorted for gene expression
and returned to secondary culture are labeled in red. (B) Secondary cultures derived from the
populations shown in (A), after 12 days of further OP9-DL1 culture. Populations sorted for
further RNA analysis from each culture came from gated regions labeled in blue. (C) Real-
time PCR analysis of gene expression in the populations derived from primary and
secondary cultures in A and B, from control (WT) and Bcl11b-deleted (KO) samples.
Measurement of spliced transcripts of Bcl11b, as a measure of exon 4 deletion efficiency,
and of the NK-specific transcription factor Zfp105. Note the selection for cells with reduced
levels of intact Bcl11b in the secondary cultures of Bcl11b-deleted cells (KO, compare red-
labeled and blue-labeled populations) and the marked upregulation of Zfp105.
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Fig. 5. Fate of Bcl11b-deleted bone marrow cells in the thymus of radiation chimeric host after
adoptive transfer
Donor cells were Lin− bone marrow cells from Bcl11b-floxed and Bcl11b wildtype mice,
each with a Cre-dependent ROSA26-YFP marker to monitor successful Cre exposure. Cells
were treated with retroviral Cre in vitro and then used to reconstitute irradiated hosts. (A)
Diagram of donor alleles. (B) Experimental scheme: in this version of the experiment, Rag-
deficient hosts were used. (C) Phenotype of donor-type YFP+ cells in the thymus of
recipient mice. Note that the Cre treatment marks a cohort of cells that tend not to persist in
the thymus normally after 12 weeks (R26R-YFP only, right panels). However, the loss of
Bcl11b (Bcl11bL2/L2 R26R-YFP) consistently increases the accumulation of donor cells in
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the thymus and the retention of Kit on the surfaces of NK-like and pro-T cell-like (arrow)
CD4−CD8− populations.
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Fig. 6. Separate regulatory subroutines in pro-T-cell commitment: selective effects of loss of
Bcl11b in the phase 1 to phase 2 transition
The figure relates the functional effects shown in Fig. 3 to the gene expression patterns
shown in Fig. 2 and their alteration in Bcl11b-deficient pro-T cells. Groups of genes that
interact in coordinated segments of the T-cell specification process are depicted in ‘layers’,
as well as groups of genes that are activated specifically when the cells escape the T-cell
program to enter NK or myeloid/dendritic cell programs. Genes shared between two
regulatory states are in parentheses. Cd3g, Cde3, and Ptcra are upregulated in two steps,
where the first (violet layer) but not the second (pink layer) can occur without Bcl11b. Note
that Bcl11b locus activation does not depend on Bcl11b function (84). Not shown: whereas
CD3 and Bcl11b gene activation is sustained in later T-cell development, some genes
induced in the DN2 stage (Ptcra, Rag1) are downregulated at β-selection.
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Table 1
Molecular definitions of T-cell identity
T-cell ‘identity genes’ Genes with transient roles in TCR assembly
Lck Ptcra (PreTCRα)
Zap70 Rag1, Rag2
Itk Dntt (Terminal deoxynucleotidyl transferase)
Lat
Cd3g (CD3γ)
Cd3d (CD3δ)
Cd3e (CD3ε)
Cd247 (CD3ζ, CD247)
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